Brief: Suven Life Sciences Announces Positive Results From Phase-2A Study Of Suvn-911
18/09/2024 07:36
Sept 18 (Reuters) - Suven Life Sciences Ltd SUVP.NS :
* SUVEN LIFE SCIENCES - ANNOUNCES POSITIVE RESULTS FROM
PHASE-2A
STUDY OF SUVN-911
* SUVEN LIFE SCIENCES - SUVN-911 STUDY FOR TREATMENT OF
MODERATE
TO SEVERE MAJOR DEPRESSIVE DISORDER
Further company coverage: SUVP.NS
((reuters.briefs@thomsonreuters.com;))
Recent news on Suven Life Sciences
See all newsBrief: Suven Life Sciences Completes Phase-1 Study Of SUVN-I6107, Advances To Phase-2
Brief: Suven Life Sciences Reports Positive DSMB Safety Review For Phase-3 Masupirdine Study
Brief: Suven Life Sciences Records 100% Patient Enrolment Milestone In Phase-2B Clinical Trial Of Ropanicant
Brief: Suven Life Sciences Says First Patient Randomized In Phase-2B Clinical Trial Of Ropanicant
Brief: Suven Life Sciences March-Quarter Consol Net Loss 439.4 Million Rupees